Mathematical Model for Evaluation of Tumor Response in Targeted Radionuclide Therapy with 211At Using Implanted Mouse Tumor
Authors:
- Yoshiharu YonekuraYYYoshiharu Yonekura
- Hiroshi TokiHTHiroshi Toki
- Tadashi WatabeTWTadashi Watabe
- Kazuko Kaneda-NakashimaKazuko Kaneda-Nakashima
- Yoshifumi ShirakamiYSYoshifumi Shirakami
- Kazuhiro OoeKOKazuhiro Ooe
- Atsushi ToyoshimaATAtsushi Toyoshima
- Hiroo NakajimaHNHiroo Nakajima
- Noriyuki TomiyamaNTNoriyuki Tomiyama
- Masako BandoMBMasako Bando
Open Access
- 15 December 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (24) , 15966
Abstract
Recent introduction of alpha-emitting radionuclides in targeted radionuclide therapy has stimulated the development of new radiopharmaceuticals. Preclinical evaluation using an animal experiment with an implanted tumor model is frequently used to examine the efficiency of the treatment method and to predict the treatment response before clinical trials. Here, we propose a mathematical model for evaluation of the tumor response in an implanted tumor model and apply it to the data obtained from the previous experiment of 211At treatment in a thyroid cancer mouse model. The proposed model is based on the set of differential equations, describing the kinetics of radiopharmaceuticals, the tumor growth, and the treatment response. First, the tumor growth rate was estimated from the control data without injection of 211At. The kinetic behavior of the injected radionuclide was used to estimate the radiation dose profile to the target tumor, which can suppress the tumor growth in a dose-dependent manner. An additional two factors, including the time delay for the reduction of tumor volume and the impaired recovery of tumor regrowth after the treatment, were needed to simulate the temporal changes of tumor size after treatment. Finally, the parameters obtained from the simulated tumor growth curve were able to predict the tumor response in other experimental settings. The model can provide valuable information for planning the administration dose of radiopharmaceuticals in clinical trials, especially to determine the starting dose at which efficacy can be expected with a sufficient safety margin.Keywords
Funding Information
- COREnet program of RCNP, Osaka University (JPMJOP1721)
- Science and Technology Agency (JST) (JPMJOP1721)
This publication has 15 references indexed in Scilit:
- Enhancement of211At Uptake via the Sodium Iodide Symporter by the Addition of Ascorbic Acid in Targeted α-Therapy of Thyroid CancerJournal of Nuclear Medicine, 2019
- The future of personalised radiotherapy for head and neck cancerThe Lancet Oncology, 2017
- 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate CancerJournal of Nuclear Medicine, 2016
- Summary of the European Directive 2013/59/Euratom: essentials for health professionals in radiologyInsights into Imaging, 2015
- ICRP Publication 127: Radiological Protection in Ion Beam RadiotherapyAnnals of the ICRP, 2014
- Redefining Relative Biological Effectiveness in the Context of the EQDX Formalism: Implications for Alpha-Particle Emitter TherapyRadiation Research, 2014
- Biodistribution and Dosimetry of Free 211 At, 125 I − and 131 I − in RatsCancer Biotherapy and Radiopharmaceuticals, 2013
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide TherapyJournal of Nuclear Medicine, 2010
- A review of dosimetry studies on external-beam radiation treatment with respect to second cancer inductionPhysics in Medicine & Biology, 2008